Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

TSX:RVX - Post Discussion

Resverlogix Corp > RVX Secures One-Year Extension of Maturity Date of Debenture
View:
Post by G1945V on Jul 22, 2020 7:08am

RVX Secures One-Year Extension of Maturity Date of Debenture

Resverlogix Secures One-Year Extension of Maturity Date of Debenture

CALGARY, Alberta, July 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed a one-year extension of the maturity date of its debenture. Mr. Donald McCaffrey, President and CEO stated, "We are very pleased that the debenture has been extended for one year, providing us with greater flexibility to create value for our shareholders through both our FDA approved BETonMACE2 final planning and our ongoing partnering discussions.”

The maturity date of the Company’s US$12 million 10% secured convertible debenture (the “Debenture”), and payment of accrued interest thereon, has been extended by one year from September 26, 2020 to September 26, 2021. In connection with the extension, the holder, a wholly-owned subsidiary of ORI Star Fund LP, received 600,000 warrants exercisable until December 31, 2024 at a price of CAD$0.74 per share.

G1945V

Comment by MarineJumper on Jul 22, 2020 8:51am
A smooth sea never made a skilled sailor. 
Comment by narmac on Jul 22, 2020 9:26am
,,,hummm,,,and this news comes well before the last hour,,,DMcC is breaking tradition here!! What could be next??.....Not sure,,,, perhaps its just my impatience,, but I dont see urgency with RVX from any point of view. Partnering ,,planning,,etc puts us into 2021 at the very earliest to start making in roads with 208 once again imo. One would think that BP would make a move with intent to ...more  
Comment by QualityTest on Jul 22, 2020 11:45am
Looks like we're in for a long wait before any significant news. Ho hum.
Comment by QualityTest on Jul 22, 2020 11:46am
And G1945,  I responded to your message.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities